Boulder’s InDevR raises $7M

BOULDER — InDevR Inc., a Boulder-based firm that makes analytical technology for the life sciences industry, recently completed a $7 million Series A funding round led by Adjuvant Capital.

The financing will support research and development and expand commercialization of InDevR’s VaxArray influenza vaccine potency testing system, according to a company news release.

“Our partnership with Adjuvant represents the next phase of company growth for us, and we are looking forward to furthering the positive impact on global health that new technologies such as VaxArray can have through process improvements and cost reduction,” InDevR CEO Kathy Rowlen said in a prepared statement. “We are energized to translate this round of financing into products that can streamline the bioprocesses associated with vaccine development and manufacturing.”

InDevR and its VaxArray system were 2018 winners of BizWest’s IQ Award in the life sciences category. 

“We hope the Series A financing will help InDevR rapidly scale its public health impact by growing the commercial footprint of the VaxArray platform in influenza vaccines and further expand the menu of essential biologic products that can benefit from faster, less expensive characterization assays,” Adjuvant founder Glenn Rockman said in a prepared statement.

 

BOULDER — InDevR Inc., a Boulder-based firm that makes analytical technology for the life sciences industry, recently completed a $7 million Series A funding round led by Adjuvant Capital.

The financing will support research and development and expand commercialization of InDevR’s VaxArray influenza vaccine potency testing system, according to a company news release.

“Our partnership with Adjuvant represents the next phase of company growth for us, and we are looking forward to furthering the positive impact on global health that new technologies such as VaxArray can have through process improvements and cost reduction,” InDevR CEO Kathy Rowlen said in a prepared statement. “We are energized to translate this round of financing into products that can streamline the bioprocesses associated with vaccine development and manufacturing.”

InDevR and its VaxArray system were 2018 winners of BizWest’s IQ Award in the life sciences category. 

“We hope the Series A financing will help InDevR rapidly scale its public health impact by growing the commercial footprint of the VaxArray platform in influenza vaccines and further expand the menu of essential biologic products that can benefit from faster, less expensive characterization assays,” Adjuvant founder Glenn Rockman said in a prepared statement.